deltatrials
Completed NA NCT00186342

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide

Sponsor: Stanford University

Conditions Acute Disease Blood and Marrow Transplant (BMT) Leukemia Leukemia, Myeloid, Chronic Myelodysplastic Syndromes Myelodysplastic Syndromes (MDS) Myeloproliferative Disorders
Interventions ablative allogeneic hematopoietic cell transplantation
Updated 5 times since 2017 Last updated: Dec 13, 2012 Started: Sep 30, 1992 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This NA trial investigates Acute Disease and Blood and Marrow Transplant (BMT) and is currently completed. Stanford University leads this study, which shows 5 recorded versions since 1992 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Sep 1992

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Stanford University
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Stanford, United States